参考文献/References:
[1]Silverman MG,Ference BA,Im K,et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions:a systematic review and meta-analysis[J]. JAMA,2016,316(12):1289-1297.
[2]Tenenbaum A,Fisman EZ,Motro M,et al. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes:therapeutic options beyond statins[J]. Cardiovasc Diabetol,2006,5:20.
[3]Varbo A,Benn M,Tybj?rg-Hansen A,et al. Remnant cholesterol as a causal risk factor for ischemic heart disease[J]. J Am Coll Cardiol,2013,61(4):427-436.
[4]Nordestgaard BG,Benn M,Schnohr P,et al. Nonfasting triglycerides and risk of myocardial infarction,ischemic heart disease,and death in men and women[J]. JAMA,2007,298(3):299-308.
[5]Martin SS,Blaha MJ,Elshazly MB,et al. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications[J]. J Am Coll Cardiol,2013,62(8):732-739.
[6]Jepsen AM,Langsted A,Varbo A,et al. Increased remnant cholesterol explains part of residual risk of all-cause mortality in 5414 patients with ischemic heart disease[J]. Clin Chem,2016,62(4):593-604.
[7]Lupton JR,Faridi KF,Martin SS,et al. Deficient serum 25-hydroxyvitamin D is associated with an atherogenic lipid profile:the Very Large Database of Lipids (VLDL-3) study[J]. J Clin Lipidol,2016,10(1):72-81.e1.
[8]Miller YI,Choi SH,Fang L,et al. Lipoprotein modification and macrophage uptake:role of pathologic cholesterol transport in atherogenesis[J]. Subcell Biochem,2010,51:229-251.
[9]Wang L,Gill R,Pedersen TL,et al. Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation[J]. J Lipid Res,2009,50(2):204-213.
[10]Kawakami A,Aikawa M,Alcaide P,et al. Apolipoprotein CⅢ induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells[J]. Circulation,2006,114(7):681-687.
[11]Olufadi R,Byrne CD. Effects of VLDL and remnant particles on platelets[J]. Pathophysiol Haemost Thromb, 2006,35(3-4):281-291.
[12]Langsted A,Madsen CM,Nordestgaard BG. Contribution of remnant cholesterol to cardiovascular risk[J]. J Intern Med,2020,288(1):116-127.
[13]Bittencourt MS,Santos RD,Staniak H,et al. Relation of fasting triglyceride-rich lipoprotein cholesterol to coronary artery calcium score (from the ELSA-Brasil Study)[J]. Am J Cardiol,2017,119(9):1352-1358.
[14]Elshazly MB,Mani P,Nissen S,et al. Remnant cholesterol,coronary atheroma progression and clinical events in statin-treated patients with coronary artery disease[J]. Eur J Prev Cardiol,2020,27(10):1091-1100.
[15]Casta?er O,Pintó X,Subirana I,et al. Remnant cholesterol,not LDL cholesterol,is associated with incident cardiovascular disease[J]. J Am Coll Cardiol,2020,76(23):2712-2724.
[16]Nordestgaard BG,Langsted A,Mora S,et al. Fasting is not routinely required for determination of a lipid profile:clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine[J]. Eur Heart J,2016,37(25):1944-1958.
[17]Nordestgaard BG,Nicholls SJ,Langsted A,et al. Advances in lipid-lowering therapy through gene-silencing technologies[J]. Nat Rev Cardiol,2018,15(5):261-272.
[18]Chapman MJ,Ginsberg HN,Amarenco P,et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease:evidence and guidance for management[J]. Eur Heart J,2011,32(11):1345-1361.
[19]Würtz P,Wang Q,Soininen P,et al. Metabolomic profiling of statin use and genetic inhibition of HMG-CoA reductase[J]. J Am Coll Cardio,2016,67(10):1200-1210.
[20]Kofink D,Eppinga RN,van Gilst WH,et al. Statin effects on metabolic profiles:data from the PREVEND IT (Prevention of Renal and Vascular End-stage Disease Intervention Trial)[J]. Circ Cardiovasc Genet,2017,10(6):e001759.
[21]Miller PE,Martin SS,Joshi PH,et al. Pitavastatin 4 mg provides significantly greater reduction in remnant lipoprotein cholesterol compared with pravastatin 40 mg:results from the short-term phase IV PREVAIL US trial in patients with primary hyperlipidemia or mixed dyslipidemia[J]. Clin Ther,2016,38(3):603-609.
[22]Tsunoda F,Asztalos IB,Horvath KV,et al. Fenofibrate,HDL,and cardiovascular disease in Type-2 diabetes:the DAIS trial[J]. Atherosclerosis,2016,247:35-39.
[23]Fruchart JC,Santos RD,Aguilar-Salinas C,et al. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm:conceptual framework and therapeutic potential:a consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation[J]. Cardiovasc Diabetol,2019,18(1):71.
[24]Aung T,Halsey J,Kromhout D,et al. Associations of Omega-3 fatty acid supplement use with cardiovascular disease risks:meta-analysis of 10 trials involving 77917 individuals[J]. JAMA Cardiol,2018,3(3):225-234.
[25]Bhatt DL,Steg PG,Miller M,et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia[J]. N Engl J Med,2019,380(1):11-22.
[26]Toth PP,Hamon SC,Jones SR,et al. Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method:analysis of 3 randomized trials versus placebo[J]. Lipids Health Dis,2016,15:28.
相似文献/References:
[1]史云聪 郭艺芳.2型糖尿病和动脉粥样硬化性心血管疾病的关系[J].心血管病学进展,2020,(5):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
SHI Yuncong,GUO Yifang.Relationship Between Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(10):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
[2]李艳茹,白世茹,李如意,等.PCSK9抑制剂在血脂代谢中的研究进展[J].心血管病学进展,2020,(7):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
LI Yanru,BAI Shiru,LI Ruyi,et al.PCSK9 Inhibitors in Lipid Metabolism[J].Advances in Cardiovascular Diseases,2020,(10):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
[3]马晓磊 朱国斌.Wnt信号与动脉粥样硬化性心血管疾病研究进展[J].心血管病学进展,2020,(8):855.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.018]
MA Xiaolei,ZHU Guobin.Wnt Signaling and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(10):855.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.018]
[4]黄毕.慢性肾脏病合并动脉粥样硬化性心血管疾病的调脂治疗进展[J].心血管病学进展,2020,(10):1065.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.016]
HUANG Bi.Lipid Management in Patients with Chronic Kidney Disease and Arteriosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(10):1065.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.016]
[5]姚雅洁 蔡恒.PCSK9抑制剂Evolocumab动脉粥样硬化性心血管疾病的研究进展[J].心血管病学进展,2020,(12):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
YAO Yajie,CAI Heng.PCSK9 Inhibitor Evolocumab and ASCVD[J].Advances in Cardiovascular Diseases,2020,(10):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
[6]蔡薇 杨堰焯 刘昊凌.甘油三酯葡萄糖乘积指数与糖尿病血管病变的研究进展[J].心血管病学进展,2022,(3):245.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
CAI Wei,YANG Yanzhuo,LIU Haoling.Triglyceride-Glucose Index and Diabetic Vascular Disease[J].Advances in Cardiovascular Diseases,2022,(10):245.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[7].胆固醇酯转移蛋白抑制剂在动脉粥样硬化性心血管疾病治疗中的研究进展[J].心血管病学进展,2022,(7):600.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
ZHU Jie,GAO Fen,XUE Shuanqin,et al.Treatment of Atherosclerotic Cardiovascular Diseases with Cholesteryl Ester Transfer Protein Inhibitor[J].Advances in Cardiovascular Diseases,2022,(10):600.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[8]欧阳运峰 李皇庆 李璐 阳军.脂蛋白a：动脉粥样硬化性心血管疾病防治新靶点[J].心血管病学进展,2022,(8):731.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.016]
OUYANG Yunfeng,LI Huangqing,LI Lu,et al.Lipoprotein A:a New Target for Prevention and Treatment of Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2022,(10):731.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.016]
[9]安海英 涂建成.载脂蛋白B与非高密度脂蛋白胆固醇在ASCVD防控中的应用价值[J].心血管病学进展,2022,(9):803.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.009]
AN Haiying,TU Jiancheng.Application Value of Apolipoprotein B and Non-High-Density Lipoprotein Cholesterol in ASCVD Prevention and Control[J].Advances in Cardiovascular Diseases,2022,(10):803.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.009]
[10]徐笑挺,戴承晔,邓毅凡,等.二十碳五烯酸在动脉粥样硬化性心血管疾病中的研究进展[J].心血管病学进展,2022,(12):1118.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.014]
XU Xiaoting,DAI Chengye,DENG Yifan,et al.Eicosapentaenoic Acid in Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2022,(10):1118.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.014]
[11]陈林滔 田清平 刘梅林.残余胆固醇预测动脉粥样硬化性心血管疾病的研究进展[J].心血管病学进展,2022,(6):492.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.004]
CHEN Lintao,TIAN Qingping,LIU Meilin.Remnant Cholesterol in Predicting Atherosclerotic Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2022,(10):492.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.004]